biostudies-literatureUnknown42(8)Michaels VRLions New Zealand District 202FOtago Southland Diabetes Research TrustBowen Family FoundationLottery Health ResearchSpinal Cord Society of New ZealandUniversity of Otago WellingtonLloyd Morgan Lions Clubs Charitable TrustStarship Foundation<h4>Aims</h4>To assess how automated insulin delivery (AID) impacts sleep in young people with type 1 diabetes and suboptimal glycaemia (HbA1c ≥ 69 mmol/mol).<h4>Methods</h4>We conducted a randomised controlled trial comparing AID to usual care in 80 participants (aged 7-25 years) over 13 weeks. Sleep was a secondary outcome assessed at baseline and 13 weeks using questionnaires (subjective) and accelerometry (objective).<h4>Results</h4>All participants completed the trial; 64 provided subjective and 40 provided objective sleep data. Participants reported poor subjective sleep quality alongside high levels of sleep disturbance and sleep-related impairment at both timepoints. At 13 weeks, sleep-related impairment improved more in the intervention group than in controls (MD = -4.7; 95% CI = Diabetic medicine : a journal of the British Diabetic Associatione70093https://www.ebi.ac.uk/biostudies/studies/S-EPMC12257429biostudies-literatureImpact of automated insulin delivery on subjective and objective sleep in children and young adults with very high HbA1c: Sleep outcomes from the CO-PILOT randomised controlled trial.PMC12257429Haszard JJWiltshire EJefferies CMichaels VRPaul RGde Bock MIBoucsein AJones SDGalland BZhou YWheeler BJMeredith-Jones KAfalseImpact of automated insulin delivery on subjective and objective sleep in children and young adults with very high HbA1c: Sleep outcomes from the CO-PILOT randomised controlled trial.<h4>Aims</h4>To assess how automated insulin delivery (AID) impacts sleep in young people with type 1 diabetes and suboptimal glycaemia (HbA1c ≥ 69 mmol/mol).<h4>Methods</h4>We conducted a randomised controlled trial comparing AID to usual care in 80 participants (aged 7-25 years) over 13 weeks. Sleep was a secondary outcome assessed at baseline and 13 weeks using questionnaires (subjective) and accelerometry (objective).<h4>Results</h4>All participants completed the trial; 64 provided subjective and 40 provided objective sleep data. Participants reported poor subjective sleep quality alongside high levels of sleep disturbance and sleep-related impairment at both timepoints. At 13 weeks, sleep-related impairment improved more in the intervention group than in controls (MD = -4.7; 95% CI = 2025-01-01T00:00:00Z2025 Aug2026-06-10T05:19:46.508Z2026-06-10T03:07:08.833ZS-EPMC122574294053417110.1111/dme.70093